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Feeney et al. (2018) make a valid argument for restrictions on the exclusivity of foundational 
technologies such as CRISPR. The issue of balancing intellectual property right with access to 
scientific and technological advancements is certainly not new. In our commentary, we argue that 
the human right to science offers a more concrete basis for governments to balance their competing 
commitments in promoting scientific development on the one hand, and ensuring benefit-sharing 
on the other, in ways that advance social justice under non-ideal conditions.  
The Human Right to Science 
The human right to science is recognized by Article 27 of the Universal Declaration of Human 
Rights (“Universal Declaration”) and Article 15 of the International Covenant on Economic, Social 
and Cultural Rights (“Covenant”). The Covenant binds States Parties (i.e., states that have ratified 
it), whereas the Universal Declaration binds all states since it has achieved customary international 
law status. As a result, states must “respect, protect, promote, and fulfill” the right to science. To 
do so, states must refrain from violating or interfering with the enjoyment of a right (respect), take 
active measures to prevent violation of the right (protect) and to advocate for, encourage, and 
otherwise support the advancement of the right (promote), and, implement the affirmative 
measures that are necessary to fully realize the right (fulfill) (Leckie, Gallagher, and Gallagher, 
20). To discharge these obligations, state actions must be deliberate, concrete, and as targeted as 
possible (Committee on Economic. Social and Cultural Rights 1991). 
At its core, the human right to science encompasses two distinct but interrelated sets of rights: the 
right of everyone to benefit from advancements in science and technology and the right to freedom 
of scientific research (Boggio and Romano 2018). Also, Article 15.2 of the Covenant demands 
that States Parties take steps “to achieve the full realization of this right … [including] those 
necessary for the conservation, the development and the diffusion of science and culture.” Human 
rights law triggers people’s right “to have a legislative and policy framework adopted and 
implemented which aims at making the benefits of scientific progress available and accessible — 
both through encouraging new scientific discoveries and through removing barriers for existing 
scientific knowledge to be used for public benefit” (London, Cox, and Coomans 2016). 
Right to Science as Policy Justification to (Re-)Calibrate Patent Exclusivity 
The issue of patent protection for foundational technologies implicates primarily the right of 
everyone to benefit from scientific and technological advancements as codified in Article 15.1.b 
of the Covenant. This provision speaks to the right to access scientific knowledge, the material 
results of scientific research and the means to access knowledge and results. As Feeney et al. 
(2018) explain, overly robust patent protection for foundational technologies may, in fact, limit 
access to the material benefits of the advancements in science and technology at multiple levels 
and could even stifle scientific progress altogether. In response, they propose a ‘non-ideal solution’ 
that is primarily directed at limiting the exclusionary rights of the patentee. In implementation, 
they argue that limitations should be imposed on certain technical fields (e.g., environment or 
health) in which patent rights are exercised, on certain types of activity that can be constrained by 
such rights, and on the exclusivity period. We agree that the proposed response is an important 
one to consider not only for the reasons that the authors have provided but also because human 
rights analysis will similarly highlight the obligation of governments to ensure that patent rights 
do not compromise the capabilities of individuals to live well.  
By human rights standards, governments must ensure that intellectual property rights do not 
preclude access to the material benefits of scientific knowledge or research and development 
(R&D). While this issue quickly turns into an empirical question—one that Feeney et al. (2018) 
acknowledge to be an open one for the contested patent rights over CRISPR—what we want to 
highlight in this commentary is that human rights law demands a shift in perspective. Intellectual 
property regimes must be continuously refined, to ensure that everyone has the capability of 
contributing to, as well as reap the benefits of, scientific innovation and technological 
advancements. 
To this end, intellectual property regimes must incorporate “flexibilities,” a term used by Farida 
Shaheed, Special Rapporteur in the field of cultural rights, in her 2012 report (United Nations 
2012). These “flexibilities” are needed to “[r]ecalibrat[e] intellectual property norms that may 
present a barrier to the right to science and establish[…] greater coherence among them seem to 
be necessary steps” to ensure that human rights standards are respected (United Nations 2012, 16). 
It is important to note that “recalibrating” does not mean voiding or disregarding intellectual 
property rights. Article 15.c of the Covenant provides that authors and inventors are entitled “to 
benefit from the protection of the moral and material interests resulting from any scientific, literary 
or artistic production.” Patents are part of this protection. However, the Covenant provides that 
this protection is not absolute but must be balanced with the other human rights considerations 
sanctioned by this instrument. The important difference between the right to science approach from 
that proposed by Feeney et al. (2018) is the responsive dynamism that is implicit in calibrating 
patent rights, as opposed to the more reactive imposition of limits entailed in the latter. 
The Right to Science is action-oriented and advances a more participatory approach to 
governance 
While justifications for the restrictions proposed by Feeney et al. (2018) are well grounded in 
social justice, it is less clear how these normative arguments can be translated into policy or 
governance measures. The right to science, particularly where it is closely aligned with the more 
established right to health, offers a more concrete basis for governments to balance their competing 
commitments in promoting scientific development on the one hand and ensuring benefit-sharing 
on the other. In addressing health inequalities, for instance, a human rights framework has been 
developed to identify human rights instruments, as well as mechanisms, by which governments 
can be held accountable under human rights law (Stronks et al. 2016).  
Applying this human rights framework to R&D governance in health systems, accountability on 
the part of governments could include proactively introducing policies that: adopt an inclusive 
understanding of innovation to develop novel technologies for unmet needs through multiple 
public- and private-sector partnerships; and promote innovative R&D models that delink research 
funding from sales revenue. In addition, governmental responsibility would include monitoring 
and assessing the overall effects of innovations on health systems for their intended and unintended 
effects over time and if they help to reduce inequalities (Bigdeli, Peters, and Wagner 2014). 
Importantly, the right to science is democratic and participatory in that it empowers individuals 
through its prescription on everyone an equal opportunity to achieve health and wellness through 
scientific R&D. Like the right to health, the right to science provides the basis for legal recourse, 
which, if successful, can result in tangible changes in the intellectual property regime. We have 
witnessed this in the context of access to innovative treatments for HIV/AIDS. Human rights 
(relating to health and science) have mobilized people and supportive institutions to hold 
governments accountable for addressing inequalities through social movements and market 
transformation (Kapstein and Busby 2013). 
In conclusion, we consider the right to science to complement the approach proposed by Feeney 
et al. (2018). Patent regimes have been constructed for particular purposes, but without having to 
completely overhaul what we have to ensure fairer outcomes, it must be supported by individual 
empowerment, accountability mechanisms and social institutions that the right to science could 
enable (Ho 2010). 
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